When the human genome was first sequenced, experts predicted they would find about 100,000 genes. The actual number has turned out to be closer to 20,000, just a few thousand more than fruit flies have. The question logically arose: how can a relatively small number of genes lay the blueprint for the complexities of the human body?
Interdisciplinary research at the University of Pennsylvania is showing how cells interact over long distances within fibrous tissue, like that associated with many diseases of the liver, lungs and other organs.
Type 1 diabetes (T1D) patients who have developed low blood sugar (hypoglycemia) as a complication of insulin treatments over time are able to regain normal internal recognition of the condition after receiving pancreatic islet cell transplantation, according to a new study led by researchers at the
Toen Castle and Randall Kamien of the School of Arts & Sciences are featured for their kirigami research.
At the turn of the millennium, the cost to sequence a single human genome exceeded $50 million, and the process took a decade to complete. Microbes have genomes, too, and the first reference genome for a malaria parasite was completed in 2002 at a cost of roughly $15 million. But today researchers can sequence a genome in a single afternoon for just a few thousand dollars.
Frequent kidney dialysis is essential for the approximately 350,000 end-stage renal disease (ESRD) patients in the United States.
An increasing number of studies show that chronically restricted sleep to less than seven hours per day impairs performance, increases the risk for errors and accidents, and is associated with negative health consequences like obesity, diabetes, and cardiovascular disease.
By Madeleine Stone @themadstone
Science fiction is often said to reflect human culture: who we are today and what we dream to be in the future. But those who write on the future also have a hand in shaping it. Indeed, many future thinkers of the past have predicted technologies of the present with uncanny accuracy.
New research about breast cancer treatment from the Perelman School of Medicine’s Justin Bekelman and Ezekiel Emanuel, also of the Whar